Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003585 · ClinicalTrials.gov registry record · Phase 1
Biological Therapy Plus Chemotherapy in Treating Patients With Metastatic or Recurrent Kidney Cancer
A Phase 1 study, sponsored by University of New Mexico.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT00003585 is a Phase 1 study that has completed, run by University of New Mexico. The registered enrollment target is 35 participants.
The verdict
NCT00003585, a Phase 1 study, has completed, sponsored by University of New Mexico.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining biological therapy with chemotherapy may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of biological therapy plus chemotherapy in treating patients with metastatic or recurrent kidney cancer.
Interventions
- DRUG fluorouracil
- BIOLOGICAL aldesleukin
- BIOLOGICAL recombinant interferon alfa
- PROCEDURE surgical procedure
- DRUG isotretinoin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 1996-08 |
| Est. Completion | 2002-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003585
The ClinicalTrials.gov registry entry for NCT00003585 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of New Mexico, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which fluorouracil is the first listed.
NCT00003585 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003585 about?
NCT00003585 is a clinical study titled "Biological Therapy Plus Chemotherapy in Treating Patients With Metastatic or Recurrent Kidney Cancer". RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining biological therapy with chemotherapy may kill more tumor cells....
What is the current status of trial NCT00003585?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 1996-08. Estimated completion is 2002-08.
What interventions are being tested in trial NCT00003585?
The interventions under investigation include: fluorouracil (DRUG), aldesleukin (BIOLOGICAL), recombinant interferon alfa (BIOLOGICAL), surgical procedure (PROCEDURE), isotretinoin (DRUG).
Who is sponsoring clinical trial NCT00003585?
This trial is sponsored by University of New Mexico, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.